Interleukin-2 protects against endothelial dysfunction induced by high glucose levels in rats

Vascular Pharmacology

Volumn 45, Issue 6, 2006, Pages 374-382

  Qian, Ling Bo ^a   Wang, Hui Ping ^a   Qiu, Wei Ling ^a   Huang, He ^b   Bruce, Iain C ^c   Xia, Qiang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diabetes; Endothelium; High glucose levels; Interleukin 2; Nitric oxide synthase; Superoxide dismutase

Indexed keywords

ACETYLCHOLINE; INTERLEUKIN 2; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; VASCULAR RING; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GLUCOSE; INTERLEUKIN-2; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 33751102161     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.06.002     Document Type: Article

References (45)

1. Baudry N., Rasetti C., and Vicaut E. Differences between cytokine effects in the microcirculation of the rat. Am. J. Physiol, Heart Circ. Physiol. 271 (1996) H1186-H1192
2. Beasley D., Schwartz J.H., and Brenner B.M. Interleukin1 induces prolonged l-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J. Clin. Invest. 87 (1991) 602-608
3. Bojunga J., Nowak D., Mitrou P.S., Hoelzer D., Zeuzem S., and Chow K.U. Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats. Diabetologia 47 (2004) 2072-2080
4. Bradbury D.A., Newton R., Zhu Y.M., Stocks J., Corbett L., Holland E.D., Pang L.H., and Knox A.J. Effect of bradykinin, TGF-beta1, IL-1beta, and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells. Am. J. Physiol., Lung Cell. Mol. Physiol. 283 (2002) L717-L725
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
6. Busse R., and Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett. 275 (1990) 87-90
7. Calles-Escandon J., and Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 22 (2001) 36-52
8. Cao C.M., Ye S., Yu H., Xu Q.S., Ye Z.G., Shen Y.L., Lu Y., and Xia Q. Interleukin-2 induced endothelium-dependent relaxation of rat thoracic aorta. Shengli Xuebao 55 (2003) 19-23
9. Cimino G., Amadori S., Cava M.C., De Sanctis V., Petti M.C., Di Gregorio A.O., Sgadari C., Vegna L., Cimino G., and Mandelli F. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. Leukemia 5 (1991) 32-35
10. Davis J.R., Giardina J.B., Green G.M., Alexander B.T., Granger J.P., and Khalil R.A. Reduced endothelial NO-cGMP vascular relaxation pathway during TNF-alpha-induced hypertension in pregnant rats. Am. J. Physiol., Regul. Integr. Comp. Physiol. 282 (2002) R390-R399
11. De Cesaris P., Starace D., Riccioli A., Padula F., Filippini A., and Ziparo E. Tumor necrosis factor-alpha induces interleukin-6 production and integrin ligand expression by distinct transduction pathways. J. Biol. Chem. 273 (1998) 7566-7571
12. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., and Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 108 (2001) 1341-1348
13. Fahim M., Hussain T., and Mustafa S.J. Relaxation of rat aorta by adenosine in diabetes with and without hypertension: role of endothelium. Eur. J. Pharmacol. 412 (2001) 51-59
14. Forstermann U., Boissel J.P., and Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 12 (1998) 773-790
15. Fragasso G., Tresoldi M., Benti R., Vidal M., Marcatti M., Borri A., Besana C., Gerundini P.P., Rugarli C., and Chierchia S. Impaired left ventricular filling rate induced by treatment with recombinant interleukin 2 for advanced cancer. Br. Heart J. 71 (1994) 166-169
16. Friesen N.T., Buchau A.S., Schott-Ohly P., Lgssiar A., and Gleichmann H. Generation of hydrogen peroxide and failure of antioxidative responses in pancreatic islets of male C57BL/6 mice are associated with diabetes induced by multiple low doses of streptozotocin. Diabetologia 47 (2004) 676-685
17. Guo X., Liu W.L., Chen L.W., and Guo Z.G. High glucose impairs endothelium-dependent relaxation in rabbit aorta. Acta Pharmacol. Sin. 21 (2000) 169-173
18. Huang X., Yuang J., Goddard A., Foulis A., James R.F., Lernmark A., Pujol-Borrell R., Rabinovitch A., Somoza N., and Stewart T.A. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44 (1995) 658-664
19. Kaye W.A., Adri M.N., Soeldner J.S., Rabinowe S.L., Kaldany A., Kahn C.R., Bistrian B., Srikanta S., Ganda O.P., and Eisenbarth G.S. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N. Engl. J. Med. 315 (1986) 920-924
20. Kilbourn R.G., Owen-Schaub L.B., Cromeens D.M., Gross S.S., Flaherty M.J., Santee S.M., Alak A.M., and Griffith O.W. NG-methyl-l-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs. J. Appl. Physiol. 76 (1994) 1130-1137
21. Levy Y., Capitant C., Houhou S., Carriere I., Viard J.P., Goujard C., Gastaut J.A., Oksenhendler E., Boumsell L., Gomard E., Rabian C., Weiss L., Guillet J.G., Delfraissy J.F., Aboulker J.P., and Seligmann M. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 Study Group. Lancet 353 (1999) 1923-1929
22. Levy Y., Gahery-Segard H., Durier C., Lascaux A.S., Goujard C., Meiffredy V., Rouzioux C., Habib R.E., Beumont-Mauviel M., Guillet J.G., Delfraissy J.F., and Aboulker J.P. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 19 (2005) 279-286
23. Li H., and Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J. Pathol. 190 (2000) 244-254
24. Llorens S., Salazar F.J., and Nava E. Assessment of the nitric oxide system in the heart, aorta and kidney of aged Wistar-Kyoto and spontaneously hypertensive rats. J. Hypertens. 23 (2005) 1507-1514
25. Maritim A.C., Sanders R.A., and Watkins III J.B. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17 (2003) 24-38
26. Mohamed-Ali V., Flower L., Sethi J., Hotamisligil G., Gray R., Humphries S.E., York D.A., and Pinkney J. Beta-adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 86 (2001) 5864-5869
27. Nys M., Preiser J.C., Deby-Dupont G., Habraken Y., Mathy-Hartert M., Damas P., and Lamy M. Nitric oxide-related products and myeloperoxidase in bronchoalveolar lavage fluids from patients with ALI activate NF-kappa B in alveolar cells and monocytes. Vascul. Pharmacol. 43 (2005) 425-433
28. Ofosu-Appiah W., Ruggiero C., Dzielak D.J., and Antzelevitch C. The effects of PEG-interleukin-2 and interleukin-2 on essential hypertension and cellular immune function in the spontaneously hypertensive rat. Clin. Exp. Hypertens. 15 (1993) 435-457
29. Parratt J.R. Nitric oxide in sepsis and endotoxaemia. J. Antimicrob. Chemother. 41 Supple A (1998) 31-39
30. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes/Metab. Rev. 14 (1998) 129-151
31. Reyes-Toso C.F., Roson M.I., Albornoz L.E., Damiano P.F., Linares L.M., and Cardinali D.P. Vascular reactivity in diabetic rats: effect of melatonin. J. Pineal Res. 33 (2002) 81-86
32. Rodriguez-Manas L., Angulo J., Vallejo S., Peiro C., Sanchez-Ferrer A., Cercas E., Lopez-Doriga P., and Sanchez-Ferrer C.F. Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 46 (2003) 556-566
33. Rosen P., Ballhausen T., Bloch W., and Addicks K. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia 38 (1995) 1157-1168
34. Sano M., Fukuda K., Kodama H., Pan J., Saito M., Matsuzaki J., Takahashi T., Makino S., Kato T., and Ogawa S. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J. Biol. Chem. 275 (2000) 29717-29723
35. Serreze D.V., and Leiter E.H. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J. Immunol. 140 (1988) 3801-3807
36. Serreze D.V., Hamaguchi K., and Leiter E.H. Immunostimulation circumvents diabetes in NOD/Lt mice. J. Autoimmun. 2 (1989) 759-776
37. Son S.M., Whalin M.K., Harrison D.G., Taylor W.R., and Griendling K.K. Oxidative stress and diabetic vascular complications. Curr. Diab. Rep. 4 (2004) 247-252
38. Tesfamariam B., Brown M.L., and Cohen R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest. 87 (1991) 1643-1648
39. Turko I.V., Marcondes S., and Murad F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am. J. Physiol, Heart Circ. Physiol. 281 (2001) H2289-H2294
40. Vega-Lopez S., Devaraj S., and Jialal I. Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J. Investig. Med. 52 (2004) 24-32
41. Wang L.L., Xia Q., Jin H.F., Chen Y.Y., Shan Q.X., Shen T., Sun Y., and Shen Y.L. Modulation of iron on the vasodilating effect of interleukin-2 in the isolated aortic ring. Zhejiang Daxue Xuebao Yixue Ban 32 (2003) 197-201
42. + exchanger inhibitor prevented endothelial dysfunction induced by high glucose. J. Cardiovasc. Pharmacol. 45 (2005) 586-590
43. Way K.J., Young H.M., and Reid J.J. Diabetes does not alter the activity and localisation of nitric oxide synthase in the rat anococcygeus muscle. J. Auton. Nerv. Syst. 76 (1999) 35-44
44. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., Seipp C.A., Rogers-Freezer L., Morton K.E., White D.E., Liewehr D.J., Merino M.J., and Rosenberg S.A. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21 (2003) 3127-3132
45. Zhou W., Zhang F., and Aune T.M. Either IL-2 or IL-12 is sufficient to direct Th1 differentiation by nonobese diabetic T cells. J. Immunol. 170 (2003) 735-740